Galapagos NV, a leading biotechnology firm, has recently finalized a significant alliance with Gilead Sciences, marking a pivotal moment in the development of advanced T-cell engager therapies. This strategic move not only expands Galapagos's footprint in immunology and oncology but also promises to accelerate the progression of innovative treatments to patients. The agreement encompasses the acquisition of Ouro Medicines' assets by Gilead, with Galapagos securing crucial intellectual property rights, assuming key development roles, and integrating Ouro's operational capabilities.

Galapagos NV Forges Landmark Partnership with Gilead Sciences for T-Cell Engager Therapies

In a major announcement on March 31, 2026, Galapagos NV (NASDAQ:GLPG) revealed a definitive agreement with Gilead Sciences (NASDAQ:GILD) concerning Gilead's strategic acquisition of Ouro Medicines, a U.S.-based biotechnology company specializing in T-cell engager therapies for autoimmune diseases. This collaboration is set to significantly bolster Galapagos's pipeline, particularly in the realm of immunology and oncology.

Under the terms of this newly established partnership, Galapagos will gain access to critical intellectual property, undertake specific development responsibilities, and integrate various operational assets, including Ouro's facilities and personnel. This integration is poised to form a new operational division directly linked to the advanced therapeutic programs.

A cornerstone of this agreement is the clinical-stage asset, gamgertamig, a BCMAxCD3 T-cell engager. Gamgertamig has already received both Fast Track and Orphan Drug Designations from the FDA for its potential in treating Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP). Registrational studies for this promising therapy are anticipated to commence as early as 2027.

Galapagos will spearhead the initial phases of development, funding the early-stage research. Subsequent, later-stage development costs will be collaboratively shared with Gilead, which will also assume leadership for global commercialization efforts outside of specified territories. Furthermore, Galapagos stands to benefit from a structured arrangement of milestone payments and tiered royalties, ranging from 20% to 23% on net sales of the developed therapies. The agreement also provides Galapagos with the flexibility to independently deploy at least $500 million of its capital, including an allocation of up to $150 million for potential share buybacks, reinforcing its financial autonomy and strategic growth initiatives.

Adding to its corporate developments, Galapagos NV also announced on March 26, 2026, the proposed appointment of Gino Santini as a non-executive independent director and future chairman of the board. This appointment awaits shareholder approval at the company's annual meeting scheduled for April 28.

This landmark agreement underscores Galapagos NV’s unwavering commitment to advancing groundbreaking therapies, particularly in its core areas of oncology and immunology. The collaboration with Gilead is expected to significantly accelerate the development and market reach of these innovative treatments, ultimately benefiting patients worldwide.

This collaboration between Galapagos and Gilead signifies a powerful synergy in the biotech sector, leveraging combined strengths to push the boundaries of medical science. For investors and healthcare professionals, it highlights the increasing importance of strategic alliances in accelerating drug development and commercialization. The focus on T-cell engager therapies represents a cutting edge in treating complex autoimmune diseases, offering hope for improved patient outcomes. This move could redefine treatment paradigms and solidify both companies' positions as leaders in innovative biopharmaceutical solutions.